IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...
China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan
The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...
Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...
CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products
Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...
Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...
Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...
Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...
Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...
Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine
Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...